Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ 61178104 (Primary) ; JNJ 61178104 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 18 Feb 2019 Results published in the Journal of Clinical Pharmacology
- 20 Jan 2017 Status changed from recruiting to completed.
- 20 May 2016 According to a Genmab media release, first participants has been dosed in this trial.